Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Jul;11(7):429-438.
doi: 10.1158/1940-6207.CAPR-17-0268. Epub 2018 Apr 24.

Evaluation of Biodistribution of Sulforaphane After Administration of Oral Broccoli Sprout Extract in Melanoma Patients With Multiple Atypical Nevi

Affiliations
Free PMC article
Randomized Controlled Trial

Evaluation of Biodistribution of Sulforaphane After Administration of Oral Broccoli Sprout Extract in Melanoma Patients With Multiple Atypical Nevi

Shawn Tahata et al. Cancer Prev Res (Phila). .
Free PMC article

Abstract

Broccoli sprout extract containing sulforaphane (BSE-SFN) has been shown to inhibit ultraviolet radiation-induced damage and tumor progression in skin. This study evaluated the toxicity and potential effects of oral BSE-SFN at three dosages. Seventeen patients who each had at least 2 atypical nevi and a prior history of melanoma were randomly allocated to 50, 100, or 200 μmol oral BSE-SFN daily for 28 days. Atypical nevi were photographed on days 1 and 28, and plasma and nevus samples were taken on days 1, 2, and 28. Endpoints assessed were safety, plasma and skin sulforaphane levels, gross and histologic changes, IHC for phospho-STAT3(Y705), Ki-67, Bcl-2, HMOX1, and TUNEL, plasma cytokine levels, and tissue proteomics. All 17 patients completed 28 days with no dose-limiting toxicities. Plasma sulforaphane levels pooled for days 1, 2, and 28 showed median postadministration increases of 120 ng/mL for 50 μmol, 206 ng/mL for 100 μmol, and 655 ng/mL for 200 μmol. Median skin sulforaphane levels on day 28 were 0.0, 3.1, and 34.1 ng/g for 50, 100, and 200 μmol, respectively. Plasma levels of proinflammatory cytokines decreased from day 1 to 28. The tumor suppressor decorin was increased from day 1 to 28. Oral BSE-SFN is well tolerated at daily doses up to 200 μmol and achieves dose-dependent levels in plasma and skin. A larger efficacy evaluation of 200 μmol daily for longer intervals is now reasonable to better characterize clinical and biological effects of BSE-SFN as chemoprevention for melanoma. Cancer Prev Res; 11(7); 429-38. ©2018 AACR.

Conflict of interest statement

JMK, SVS, JHB, JWF are on a patent of BSE-SFN. No other conflicts of interest to declare.

Figures

Figure 1
Figure 1
(A) Post-treatment increase in plasma sulforaphane concentration, stratified by dose group. (B) Day 28 post-treatment skin sulforaphane concentration, stratified by dose group. Data are presented in box plots.
Figure 2
Figure 2
Representative skin biopsy specimens with immunohistochemical (IHC) staining for pSTAT3, Ki-67, Bcl-2, and TUNEL showing varying degrees of positivity in nevic melanocytes, with positive controls. pSTAT3, Bcl-2, and TUNEL were graded as 0+ (negative), 1+ (less or few positive), 2+ (moderate or weakly positive), 3+ (strong or positive), or 4+ (very strong); Ki-67 was graded as 0+ (negative) or 1+ positive. IHC for heme oxygenase not shown. *No specimens demonstrated 4+ pSTAT3 staining or 2+ Bcl-2 staining. Images were obtained at 10× objective magnification using a Leica microscope.
Figure 3
Figure 3
Paired representative gross photographic images of nevi pre- and post-treatment demonstrating various gross changes, including (A) increase in size but decrease in color asymmetry, (B) increase in shape asymmetry, (C) increase in border irregularity, (D) increase in color asymmetry, (E) decrease in size, and (F) decrease in shape asymmetry and border irregularity. (G) Demonstration of image analysis techniques used to delineate border (upper left), diameter (upper right), major and minor axes (lower left), and convex hull (lower right).

Similar articles

See all similar articles

Cited by 5 articles

Publication types

MeSH terms

Feedback